DK1132086T3 - Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt - Google Patents

Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt

Info

Publication number
DK1132086T3
DK1132086T3 DK01300690T DK01300690T DK1132086T3 DK 1132086 T3 DK1132086 T3 DK 1132086T3 DK 01300690 T DK01300690 T DK 01300690T DK 01300690 T DK01300690 T DK 01300690T DK 1132086 T3 DK1132086 T3 DK 1132086T3
Authority
DK
Denmark
Prior art keywords
acute
agonists
renal failure
prostaglandin
chronic renal
Prior art date
Application number
DK01300690T
Other languages
English (en)
Inventor
David Duane Thompson
Vishwas Madhav Paralkar
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1132086T3 publication Critical patent/DK1132086T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01300690T 2000-01-31 2001-01-25 Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt DK1132086T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17896800P 2000-01-31 2000-01-31

Publications (1)

Publication Number Publication Date
DK1132086T3 true DK1132086T3 (da) 2006-08-28

Family

ID=22654657

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01300690T DK1132086T3 (da) 2000-01-31 2001-01-25 Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt

Country Status (18)

Country Link
US (1) US6610719B2 (da)
EP (1) EP1132086B1 (da)
JP (2) JP3839261B2 (da)
KR (1) KR100419684B1 (da)
AT (1) ATE327751T1 (da)
AU (1) AU774569B2 (da)
CA (1) CA2332687A1 (da)
CO (1) CO5261529A1 (da)
CY (1) CY1105299T1 (da)
DE (1) DE60120007T2 (da)
DK (1) DK1132086T3 (da)
ES (1) ES2263557T3 (da)
HU (1) HUP0100495A3 (da)
IL (1) IL141120A0 (da)
NZ (1) NZ509632A (da)
PE (1) PE20011048A1 (da)
PT (1) PT1132086E (da)
ZA (1) ZA200100827B (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024647A1 (fr) * 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
DE60130675T2 (de) 2000-11-27 2008-01-24 Pfizer Products Inc., Groton Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
EP1408961B1 (en) * 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
KR100826866B1 (ko) 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
AU2002340282B2 (en) 2001-10-23 2007-08-09 Merck Serono Sa Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
AU2003211574A1 (en) 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2003233729B2 (en) * 2002-06-06 2007-10-04 Merck Frosst Canada Ltd 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
JP4754820B2 (ja) * 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγラクタムおよびその使用
HUE029417T2 (en) 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
FI20030015A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Menetelmä munuaisten vajaatoiminnan hoitamiseksi
EP1586564B1 (en) * 2003-01-21 2012-11-28 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medicinal uses thereof
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20080306155A1 (en) * 2004-09-16 2008-12-11 Roman Richard J Method for treating renal disease
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
EP1952823A1 (en) 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
JP5836262B2 (ja) 2009-03-19 2015-12-24 フェイト セラピューティクス， インコーポレイテッド サイクリックａｍｐエンハンサーおよび／またはｅｐリガンドを含む組成物、ならびにこれを調製および使用する方法
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
CN102933233A (zh) 2010-06-17 2013-02-13 日东电工株式会社 肾纤维化处理剂
ES2654994T3 (es) 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas
KR20140056250A (ko) 2011-08-02 2014-05-09 오노 야꾸힝 고교 가부시키가이샤 좌심실 확장 기능 개선제
SG10201602423TA (en) 2011-09-30 2016-05-30 Bluebird Bio Inc Compounds For Improved Viral Transduction
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
WO2013082241A2 (en) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Improved methods of treating ischemia
WO2014069401A1 (ja) 2012-10-29 2014-05-08 株式会社カルディオ 肺疾患特異的治療剤
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
EP2968416A4 (en) 2013-03-15 2016-08-17 Fate Therapeutics Inc BIOLOGICAL ACTIVITY TESTING OF CELLS FOR A THERAPEUTIC POTENTIAL
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
BR112016017041B1 (pt) 2014-01-24 2023-09-26 Am-Pharma B.V Proteína quimérica isolada, vetor, método para produzir a proteína quimérica isolada e composição
PL3461891T3 (pl) 2014-01-24 2020-11-16 Am-Pharma B.V. Przetwarzanie końcowe fosfatazy alkalicznej
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
EP3770252A1 (en) 2015-01-26 2021-01-27 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
EP3307747A4 (en) 2015-06-12 2019-02-27 Simon Fraser University AMIDE-LINKED EP4-BISPHOSPHONATE AGONIST COMPOUNDS AND USES THEREOF
WO2017015320A1 (en) 2015-07-21 2017-01-26 Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
CA3014078A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066692A (en) 1972-10-30 1978-01-03 Merck & Co., Inc. 11,12-secoprostaglandins
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
SE7414770L (da) 1973-12-13 1975-06-16 Merck & Co Inc
US3991087A (en) 1973-12-13 1976-11-09 Merck & Co., Inc. 8-Halo-11,12-secoprostaglandins
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en) 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
CA1077948A (en) * 1976-08-06 1980-05-20 Albin J. Nelson 1,-5 disubstituted-2-pyrrolidones and processes for their production
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4112236A (en) 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5716835A (en) 1994-05-05 1998-02-10 Allergan, Inc. Nucleic acid encoding a novel human EP prostaglandin receptor
US5807895A (en) * 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6531485B2 (en) 1997-06-23 2003-03-11 Pfizer Inc. Prostaglandin agonists
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (en) * 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
WO2000054808A1 (fr) * 1999-03-16 2000-09-21 Toray Industries, Inc. Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant

Also Published As

Publication number Publication date
DE60120007T2 (de) 2006-11-16
JP3839261B2 (ja) 2006-11-01
ZA200100827B (en) 2002-07-30
JP2001233792A (ja) 2001-08-28
CY1105299T1 (el) 2010-03-03
US20010041729A1 (en) 2001-11-15
HU0100495D0 (en) 2001-03-28
KR100419684B1 (ko) 2004-02-21
AU774569B2 (en) 2004-07-01
EP1132086B1 (en) 2006-05-31
PE20011048A1 (es) 2001-10-19
AU1672201A (en) 2001-08-02
EP1132086A2 (en) 2001-09-12
NZ509632A (en) 2003-01-31
EP1132086A3 (en) 2002-01-09
KR20010078209A (ko) 2001-08-20
HUP0100495A2 (en) 2002-10-28
DE60120007D1 (de) 2006-07-06
ATE327751T1 (de) 2006-06-15
PT1132086E (pt) 2006-09-29
CA2332687A1 (en) 2001-07-31
ES2263557T3 (es) 2006-12-16
JP2006182788A (ja) 2006-07-13
IL141120A0 (en) 2002-02-10
CO5261529A1 (es) 2003-03-31
HUP0100495A3 (en) 2003-12-29
US6610719B2 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
DK1132086T3 (da) Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
NO20030374L (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
DK1542977T3 (da) 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
DK2314319T3 (da) Sammensætninger til rensning af colon
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA200601912A1 (ru) Применение пептидных соединений для профилактики и лечения хронической головной боли
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
BRPI0516128A (pt) uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
DE60029242D1 (de) Arzneien zur begleitenden behandlung von glaukomen
ATE410235T1 (de) Behandlung von ballastwasser
ATE443044T1 (de) Tace inhibitoren
WO2002041894A3 (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
DK1301475T3 (da) Arylsulfonamider, som serotoninantagonist til behandling af obesitet
DK1642576T3 (da) Anvendelse af pyrrolderivater til at bekæmpe angst
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DK1513529T3 (da) Tredobbelte monoamin-genoptagelsesinhibitorer til behandling af kronisk smerte
ATE380899T1 (de) Zungenvorrichtung für weichen
BR0113202A (pt) Compostos de trioxepano
DK1196184T3 (da) Sammensætninger til behandling af seksuel dysfunktion
SE0303489D0 (sv) New use VII